Showing 611-620 of 9295 results for "".
The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Starting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance ofPart 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benThe Treatment Landscape for Children and Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37153/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, provides an overview of current therapeutic options for pediatric atopic dermatitis patients.Clinical Questions About Isotretinoin and More
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/clinical-questions-about-isotretinoin-and-more/54661/Lawrence Eichenfield, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.“Ask Me Anything” Mentorship Session: Dr. Natasha Mesinkovska on Academia, Alopecia Areata, and More
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/ask-me-anything-mentorship-session-dr-natasha-mesinkovska-on-academia-alopecia-areata-and-more/48814/Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses how she navigated her unique career path, how she balances her various responsibilities now, and more in an "Ask Me Anything" mentorship session.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeHilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.